Streetbeat News

Corporate Responsibility

CYCC

CYCCP

Cyclacel Pharmaceuticals, Inc. received a $2.9M R&D tax credit from HMRC for costs incurred in 2023, with an additional $0.8M expected. This support aids in developing precision medicine for oncology.

Portfolio Pulse from Benzinga Newsdesk

March 06, 2024 | 2:25 pm

BE

SHEL

Bloom Energy has entered into agreements with Shell to explore opportunities for renewable hydrogen energy projects, aiming to advance decarbonization through emerging SOEC technology.

Portfolio Pulse from Benzinga Newsdesk

March 06, 2024 | 2:04 pm

HSCS

HeartSciences has been granted a patent in Canada for its MyoVista Wavelet Technology, a significant development in the company's intellectual property portfolio. This patent enhances HeartSciences' position in the medical technology market, potentially leading to increased market share and revenue through the protection and commercialization of its innovative technology.

Portfolio Pulse from Benzinga Newsdesk

March 06, 2024 | 2:02 pm

CETX

Cemtrex Inc. (NASDAQ:CETX) announced its subsidiary, Vicon, will begin the beta release of an AI gun detection feature in Q2 2024, aiming for full commercialization in the second half of 2024. This edge-based solution is designed to enhance public safety by detecting armed individuals in surveillance footage, offering a cost-effective alternative to server-based systems. The technology, developed in collaboration with partners, aims to provide real-time alerts and rapid response to potential threats, addressing the urgent need for innovative solutions to gun violence in the U.S.

Portfolio Pulse from Benzinga Newsdesk

March 06, 2024 | 1:48 pm

GBLI

Global Indemnity Group, LLC (NYSE:GBLI) announced a 40% increase in its quarterly dividend from $0.25 to $0.35 per share, payable on March 28, 2024, to shareholders of record as of March 21, 2024. This increase reflects GBLI's strong financial performance, capital and reserve positions, liquidity, and balance sheet. Since going public, GBLI has repaid all debt and returned over $600 million to shareholders. Future dividends are subject to Board discretion based on financial health and other factors.

Portfolio Pulse from Benzinga Newsdesk

March 06, 2024 | 1:46 pm

XTKG

X3 Holdings Co., Ltd. (NASDAQ:XTKG) announced a 6% common stock dividend to be distributed on May 27, 2024, to shareholders of record as of April 26, 2024. This move aims to boost shareholder value and liquidity, reflecting the company's commitment to its investors and confidence in future growth.

Portfolio Pulse from Benzinga Newsdesk

March 06, 2024 | 1:41 pm

ATOS

Data from Atossa Therapeutics' Phase 2 EVANGELINE clinical trial will be presented at the American Association for Cancer Research Annual Meeting. This presentation could potentially impact the perception of Atossa's progress in developing treatments for cancer.

Portfolio Pulse from Benzinga Newsdesk

March 06, 2024 | 1:31 pm

ABBV

AbbVie and its subsidiary Allergan Aesthetics will present 29 abstracts, including three late-breaking presentations, at the 2024 AAD Meeting in San Diego, showcasing their commitment to dermatology and aesthetics. The presentations will cover efficacy, safety, and durability data across their portfolios, including data on RINVOQ and SKYRIZI for various dermatologic conditions, and Phase 3 studies of BOTOX Cosmetic and JUVÉDERM VOLUMA XC for aesthetic treatments.

Portfolio Pulse from Benzinga Newsdesk

March 06, 2024 | 1:15 pm

CTSH

MSFT

Cognizant and Microsoft have announced a collaboration to integrate generative AI into healthcare administration through the TriZetto platform, which is powered by Azure OpenAI Service. This initiative aims to reduce hidden costs and improve patient outcomes for millions of Americans.

Portfolio Pulse from Benzinga Newsdesk

March 06, 2024 | 1:14 pm

BCTX

BriaCell Therapeutics Corp. (NASDAQ:BCTX, TSX:BCT) announced it will present three posters at the 2024 AACR Annual Meeting, showcasing its advancements in immunotherapies for CNS metastasis and ADC-resistant breast cancer. The presentations will cover the efficacy of Bria-IMT regimen, SV-BR-1-GM treatment, and the Bria-OTS immunotherapy platform.

Portfolio Pulse from Benzinga Newsdesk

March 06, 2024 | 1:14 pm